Special oil may tame seizures in rare brain energy disorder
NCT ID NCT02014883
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested triheptanoin oil in 20 people with GLUT1 deficiency syndrome, a rare genetic condition that prevents glucose from properly fueling the brain. The goal was to see if this special oil could reduce the number of seizures and abnormal movement episodes. Participants took the oil and were monitored for safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- triheptanoin oil
- What this could lead to
- If it works, this could provide a new treatment option to reduce seizures and abnormal movements in people with GLUT1 deficiency syndrome.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply to all patients. There is also a risk of side effects like elevated propionylcarnitine levels, requiring dose adjustments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
20 people
The number who actually took part.
- Started
-
Dec 2013
- Finished
-
Jul 2019
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
3 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Mutation in SLC2A1 gene * Age \> 3 years * Patient with history/frequency of seizures or movement disorders documented at least 3 months prior to the beginning of the study * Covered by french social security * Patients who freely agree to participate in this study and understand the nature, risks and benefits of this study and give their written informed consent. (In addition to the requirement for the consent of parents or the legal representative, adolescents can provide additional informed consent to participate in clinical trials) Exclusion Criteria: * Evidence of psychiatric disorder * Attendant neurological disorder * Comorbid medical condition that would render them unsuitable for the study, e.g. HIV, diabetes * Pregnant or parturient or lactating women * Unwillingness to be informed in case of abnormal MRI * Failure to give written informed consent * Unable to understand the protocol * Unable to participate to the whole study * Absence of signed informed consent * Persons deprived of their liberty by judicial or administrative decision * Person subject to an exclusion period for another research * Subjects with exclusion criteria required by french law
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLUT1 deficiency syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brain and Spine Institute
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.